AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these immune proteins can do more than that: They also activate other components of ...

BigHat Biosciences, a biotechnology company, has entered a strategic collaboration with Eli Lilly and Company.

In-Licensing of novel activin E antibody underscores iBio’s commitment to delivering meaningful benefits to patients living ...

AI is enabling the development of a next generation of drugs that can more precisely target cancer cells while sparing ...

GenAI offers a realistic path forward in tackling previously undruggable targets, with the potential to reshape the entire ...

Right now, Hartung says scientists can use AI to pull and analyze millions of scientific papers as a way of screening chemical substances for potential problems instead of subjecting zebrafish and ...

Animal testing requirements for monoclonal antibodies and other medications will be “reduced, refined or potentially replaced ...

BigHat Biosciences, a Californian biotech with a machine learning (ML)-guided antibody discovery and development platform, ...

Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these immune proteins can do more ...